Tinavi Medical Technologies Co.Ltd(688277) independent director
Independent opinions on relevant matters of the 11th meeting of the 5th board of directors of the company
According to the articles of association, working system of independent directors and other relevant provisions, As an independent director of Tinavi Medical Technologies Co.Ltd(688277) (hereinafter referred to as “the company”), we, in a serious and responsible manner, on the basis of understanding the relevant situation, after careful consideration and based on independent judgment, express the following independent opinions on the relevant matters considered at the 11th meeting of the Fifth Board of directors of the company:
1. Proposal on adjusting the company’s plan to issue A-Shares to specific objects in 2021
The company’s issuance of shares to specific objects after this adjustment complies with the company law, the securities law, the measures for the administration of securities issuance registration of companies listed on the science and Innovation Board (for Trial Implementation) and other laws and regulations, normative documents and the articles of association The provisions are in line with the long-term development of the company, and there is no situation that damages the interests of the company and its shareholders, especially small and medium-sized shareholders. We agree with the contents of the motion.
2. On
<公司 2021 年度向特定对象发行 A 股股票预案（修订稿）>
The company’s adjusted plan for issuing A-Shares to specific objects in Tinavi Medical Technologies Co.Ltd(688277) 2021 (Revised Draft) complies with the company law, the securities law, the measures for the administration of securities issuance registration of companies listed on the science and Innovation Board (for Trial Implementation) and other laws, regulations, normative documents and the articles of Association The provisions are in line with the actual situation of the company, the investment direction of the raised funds is in line with the relevant national policies and the development direction of the company, and is in line with the long-term development objectives of the company and the interests of shareholders. We agree with the contents of the motion.
3. On
<公司 2021 年度向特定对象发行 A 股股票方案的论证分析报告（修订稿）>
Proposal for
Demonstration and analysis report on Tinavi Medical Technologies Co.Ltd(688277) 2021 A-share issuance scheme to specific objects (Revised Version) prepared by the company Comprehensively considering the current situation and development trend of the company’s industry, development strategy, financing planning, financial status, capital demand and other conditions, this paper fully demonstrates the necessity of the issuance of securities and the selection of their varieties, which is in line with the interests of the company and all shareholders, does not damage the interests of the company and shareholders, especially small and medium-sized shareholders, and complies with relevant laws Regulations and normative documents. We agree with the contents of the motion.
4. On
<公司 2021年度向特定对象发行股票募集资金使用的可行性分析报告（修订稿）>
Proposal for
The investment project raised by this issuance conforms to relevant national industrial policies and the company’s overall development strategy in the future, is conducive to enhancing the company’s operating ability and profitability, promoting the sustainable development of the company, and is in line with the interests of the company and all shareholders. We agree with the contents of the motion.
5. On
<公司2021年度向特定对象发行A股股票摊薄即期回报与公司采取填补措施及相关主体承诺（修订稿）>
Proposal for
The company’s commitment that the measures of issuing A-Shares to specific objects to fill the immediate return can be effectively fulfilled is in line with the several opinions of the State Council on further promoting the healthy development of the capital market (GF [2014] No. 17) and the opinions of the general office of the State Council on further strengthening the protection of the legitimate rights and interests of small and medium-sized investors in the capital market (GBF [2013] No. 110) The guiding opinions on matters related to IPO and refinancing, major asset restructuring and diluted immediate return (CSRC announcement [2015] No. 31) and other relevant provisions are in line with the interests of the company and shareholders. We agree with the contents of the proposal.
Independent director: Dai Changjiu, Wang Guangzhi, Li Yan date: December 22, 2021
